Skip to main content

Table 3 Selected single nucleotide polymorphisms patient data

From: Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.

SNPs No of patients (%) p-value
ITP IP
MDR1 C3435T
Polymorphisms
 CT 13 (59.1) 14 (66.6) 1
 CC 4 (18.2) 3 (14.3)  
 TT 5 (22.7) 4 (19)  
MDR1 G2677 T
Polymorphisms
 GT 5 (22.7) 5 (23.8) 0.904
 GG 15 (68.2) 13 (61.9)  
 TT 2 (9.1) 3 (14.3)  
ERCC1 C8092A
Polymorphisms
 CA 9 (40.9) 8 (38.1) 1
 CC 11 (50) 10 (47.6)  
 AA 2 (9.1)) 3 (14.3)  
ERCC1 N118 N
Polymorphisms
 CT 8 (36.4) 12 (57.1) 0.371
 CC 3 (13.6) 3(14.3)  
 TT 11 (50) 6 (28.6)  
  1. ITP Ifosfamide Paclitaxel Cisplatin, IP Ifosfamide Cisplatin